Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,633.96
(0.38%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Amplia Therapeutics Ltd

ATX

ASX

Amplia Therapeutics Limited (ATX) is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Latest Posts

Line Chart with Gradient
Price
$0.088
-0.002 (-2.22%)
At Close 22/11 (AEST)
Related Companies
PERCHERON THERAPEUTICS LIMITED
$PER
VECTUS BIOSYSTEMS LIMITED
$VBS
CLINUVEL PHARMACEUTICALS LIMITED
$CUV
MELODIOL GLOBAL HEALTH LIMITED
$ME1DE
TRYPTAMINE THERAPEUTICS LIMITED
$TYP

Leave a Comment on ATX


Comments for ATX

    Latest Posts

    amplia-therapeutics-asx-atx-initiates-trading-halt-for-capital-raising-atx
    Health Care $ATX
    Amplia Therapeutics (ASX: $ATX) initiates trading halt for capital raisingHalt pending institutional offer outcome as part of broader capital raising strategy
    October 30, 2024
    amplia-therapeutics-asx-atx-progresses-pancreatic-cancer-trial-atx
    Health Care $ATX

    Amplia Therapeutics (ASX: $ATX) progresses pancreatic cancer trial

    Phase 2a trial achieves required response rate with narmafotinib combination therapy

    September 23, 2024
    amplia-therapeutics-asx-atx-secures-fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer-atx
    Health Care $ATX

    Amplia Therapeutics (ASX: $ATX) secures fda fast track designation for narmafotinib in advanced pancreatic cancer

    FDA fast track designation facilitates expedited review for promising FAK inhibitor in pancreatic cancer treatment

    September 20, 2024
    amplia-therapeutics-asx-atx-secures-key-chemical-form-patent-in-europe-and-japan-atx
    Health Care $ATX

    Amplia Therapeutics (ASX: $ATX) secures key chemical form patent in europe and japan

    Patent protection for narmafotinib extended to at least 2040 in major markets

    August 7, 2024
    amplia-therapeutics-asx-atx-completes-recruitment-for-phase-2a-accent-trial-atx
    Health Care $ATX

    Amplia Therapeutics (ASX: $ATX) completes recruitment for phase 2a ACCENT trial

    Phase 2a trial explores narmafotinib in combination with standard-of-care chemotherapy for advanced pancreatic cancer patients

    July 4, 2024
    amplia-therapeutics-asx-atx-requests-trading-halt-for-entitlement-offer-process-atx
    Health Care $ATX

    Amplia Therapeutics (ASX: $ATX) requests trading halt for entitlement offer process

    Company to release announcement regarding capital raising to end trading halt

    April 12, 2024
    amplia-therapeutics-asxatx-receives-approval-for-phase-2-accent-pancreatic-cancer-trial-in-korea-atx
    Health Care $ATX

    Amplia Therapeutics (ASX:ATX) receives approval for phase 2 accent pancreatic cancer trial in korea

    Korean regulator approves clinical trial for narmafotinib in combination with gemcitabine and Abraxane®

    December 3, 2023

    ATX

    $ATX

    Amplia Therapeutics (ASX: $ATX) initiates trading halt for capital raising

    Halt pending institutional offer outcome as part of broader capital raising strategy

    ATX

    $ATX

    Amplia Therapeutics (ASX: $ATX) progresses pancreatic cancer trial

    Phase 2a trial achieves required response rate with narmafotinib combination therapy

    ATX

    $ATX

    Amplia Therapeutics (ASX: $ATX) secures fda fast track designation for narmafotinib in advanced pancreatic cancer

    FDA fast track designation facilitates expedited review for promising FAK inhibitor in pancreatic cancer treatment

    ATX

    $ATX

    Amplia Therapeutics (ASX: $ATX) secures key chemical form patent in europe and japan

    Patent protection for narmafotinib extended to at least 2040 in major markets

    ATX

    $ATX

    Amplia Therapeutics (ASX: $ATX) completes recruitment for phase 2a ACCENT trial

    Phase 2a trial explores narmafotinib in combination with standard-of-care chemotherapy for advanced pancreatic cancer patients

    ATX

    $ATX

    Amplia Therapeutics (ASX: $ATX) requests trading halt for entitlement offer process

    Company to release announcement regarding capital raising to end trading halt

    ATX

    $ATX

    Amplia Therapeutics (ASX:ATX) receives approval for phase 2 accent pancreatic cancer trial in korea

    Korean regulator approves clinical trial for narmafotinib in combination with gemcitabine and Abraxane®

    Related Companies
    ADALTA LIMITED
    $1AD
    BPH GLOBAL LTD
    $BP8DD
    PATRYS LIMITED
    $PAB
    CLINUVEL PHARMACEUTICALS LIMITED
    $CUV
    PARADIGM BIOPHARMACEUTICALS LIMITED..
    $PAR

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions